Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

BACKGROUND: Dupuytren’s disease is a common fibrotic condition that causes the fingers to flex irreversibly into the palm. Treatments for late-stage disease all have limitations, and there is no approved treatment for early-stage disease. We identified tumour necrosis factor as a therapeutic target...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanchahal, Jagdeep, Ball, Catherine, Rombach, Ines, Williams, Lynn, Kenealy, Nicola, Dakin, Helen, O’Connor, Heather, Davidson, Dominique, Werker, Paul, Dutton, Susan J, Feldmann, Marc, Lamb, Sarah E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613263/
https://www.ncbi.nlm.nih.gov/pubmed/35949922
http://dx.doi.org/10.1016/S2665-9913(22)00093-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613263/
https://www.ncbi.nlm.nih.gov/pubmed/35949922
http://dx.doi.org/10.1016/S2665-9913(22)00093-5

Ejemplares similares